Reck M, Paz-Ares LG. Response to the letter Re: "Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial". Eur J Cancer 2025;226:115610.
PMID: 40651389